OakChart

Connect Biopharma Holdings Ltd

CNTBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.6889+0.0067 (0.98%)
2026-11-12 00:07 CET
Market cap
42.96 USD m
Revenue, TTM
2.95 USD m
Net income, TTM
-68.99 USD m
Free cash flow, TTM
-61.54 USD m
EPS diluted, TTM
-1.20
P/E
-
Compare

Price

CNTB against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.0082.8M165.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CNTBclose 0.6920-day 0.8050-day 1.11200-day 2.130.69

82.0% under the 52-week high of 3.82 on 27 Mar 2026. 52-week low 0.68 on 10 Nov 2026. Last 15 sessions, 30.3% high to low

Volume 0.08× normal · the line is the 50-bar volume average

Profile

CNTB
52-week range, 0% of the way up
0.683.82

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.

IndexRUT
Employees64
IPOMar 19, 2021
Beta-0.02
ATR, 14d0.08
Rel volume0.08
Short float22.40%
Insider own72.85%
Inst own27.36%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap43.38M
Enterprise Value12.49M
Income-68.99M
Sales2.95M
Book/sh0.43
Cash/sh0.50
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees64
IPOMar 19, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S14.71
P/B1.62
P/C1.38
P/FCF-
EV/EBITDA-
EV/Sales4.23
Quick Ratio2.37
Current Ratio2.37
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.20
EPS next Y-0.81
EPS next Q-0.27
EPS this Y1.09%
EPS next Y20.19%
EPS next 5Y7.86%
EPS past 3/5Y22.61% 12.68%
Sales past 3/5Y- -
EPS Y/Y TTM-322.65%
Sales Y/Y TTM-
EPS Q/Q-18.29%
Sales Q/Q5666.67%
EarningsAug 12 AMC
EPS/Sales Surpr.14.50% 271.31%

Ownership

Insider Own72.85%
Insider Trans0.33%
Inst Own27.36%
Inst Trans-0.66%
ROA-109.34%
ROE-140.51%
ROIC-254.92%
Gross Margin-
Oper. Margin-2384.49%
Profit Margin-2336.30%
SMA20-13.90%
SMA50-37.77%
SMA200-67.59%
Trades-

Technical

Shs Outstand62.97M
Shs Float17.10M
Short Float22.40%
Short Ratio0.97
Short Interest3.83M
52W High3.82 -81.97%
52W Low0.68 1.31%
Volatility9.29% 8.09%
ATR (14)0.08
RSI (14)28.98
Beta-0.02
Rel Volume0.08
Avg Volume3.93M
Volume301,259

Performance

Perf Week-11.74%
Perf Month-25.02%
Perf Quarter-72.88%
Perf Half Y-71.88%
Perf YTD-75.57%
Perf Year-54.68%
Perf 3Y-58.50%
Perf 5Y-95.21%
Perf 10Y-
Recom1.00
Target Price6.03
Prev Close0.68
Price0.69
Change %0.98%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Oct 12, 2026ResumedLLeerink PartnersOutperform$4+480.6%
Jun 26, 2026InitiatedPPiper SandlerOverweight$7+916.1%
May 26, 2026InitiatedCCanaccord GenuityBuy$6+771.0%
May 21, 2026InitiatedCCantor FitzgeraldOverweight$4+480.6%
Dec 01, 2025InitiatedLLake StreetBuy$9+1,206.4%
Oct 31, 2025InitiatedBBTIG ResearchBuy$10+1,351.6%
Jun 12, 2025InitiatedHH.C. WainwrightBuy$7+916.1%
Mar 04, 2024InitiatedHH.C. WainwrightBuy$7+916.1%
Apr 13, 2021InitiatedSSVB LeerinkOutperform$32+4,545.1%
Apr 13, 2021InitiatedPPiper SandlerOverweight

Peers

Mkt cap
TickerCompanyMkt cap
UPBUpstream Bio Inc175.27M
REGNRegeneron Pharmaceuticals Inc99.23B
KYMRKymera Therapeutics Inc11.51B
SNYSanofi ADR115.43B
EVMNEvommune Inc312.84M
ZURAZura Bio Ltd137.75M
INSMInsmed Inc26.49B
ORKAOruka Therapeutics Inc7.27B
ALMSAlumis Inc883.74M
AZNAstrazeneca plc287.66B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Huang JamesDirectorMay 29 '26Buy2.48150,000371,61013,310,000Jun 02 04:30 PM
Huang JamesDirectorMar 31 '26Buy3.451,160,0004,002,00013,160,000Apr 01 04:30 PM
Panacea Innovation Limited10% OwnerNov 24 '25Proposed Sale3.002,000,0006,000,000Nov 24 09:45 PM
Wei Zheng10% OwnerNov 21 '25Proposed Sale3.19650,0002,073,500Nov 21 03:32 PM
BioFortune Inc10% OwnerNov 18 '25Proposed Sale2.49500,0001,245,000Nov 18 07:06 AM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B
ITWOProShares Russell 2000 High Income ETFAUM: 178.20M
URTYProShares UltraPro Russell2000 3x SharesAUM: 277.82M

News

latest 14 of 200
  • Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program (InvestorsHub) +10.89%
  • Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation (GlobeNewswire)
  • Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance (InvestorsHub) -32.17%
  • Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation (GlobeNewswire)
  • Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) -30.07%
  • Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +9.01%
  • Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma (GlobeNewswire)
  • Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire) +14.53% -8.58%
  • Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis (GlobeNewswire)
  • Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update (GlobeNewswire) -9.66%
  • Connect Biopharma Announces $20.2 Million Private Placement Financing (GlobeNewswire) -15.94%
  • Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study (GlobeNewswire)
  • Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.270-0.316-0.2732.770.758
2026Q12026-05-12-0.340-0.280-0.3430.170.005
2025Q42026-03-31-0.269-0.302-0.2700.030.005
2025Q32025-11-12-0.311-0.240-0.3090.000.004
2025Q22025-08-13-0.230-0.220-0.2320.000.002
2025Q12025-05-15-0.190-0.260-0.1860.000.001
2024S22025-03-31-0.420-0.374-0.4191.90-1
2024S12024-09-050.138-0.13823.80--
2023S22024-04-16-0.548-0.229-0.5500.0020.902
2023S12023-09-12-0.535-0.893-1.0090.000.002
2022Q22022-09-13-1.020--0.00-1
2022Q12022-06-01-0.491-0.516-0.4910.000.001
2021Q42022-04-07-0.978-0.691-0.9780.000.002
2021Q32021-12-01-0.482-0.480-0.4820.000.001
2021Q22021-11-02-3.141--3.1410.00-1
2021Q12021-07-21-0.209--0.4000.00--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4.062--1.9630.00-
2021FY-3.965-3.858-3.8840.790.00
2022FY-2.106-2.146-2.1500.000.00
2023FY-1.080-0.762-1.1280.0020.90
2024FY-0.280-0.232-0.28325.9924.33
2025FY-0.996-1.026-1.0050.060.08
2026FY--1.018--8.20
2027FY--0.813--14.99
2028FY--0.806--13.40
2029FY--0.747--19.58
2030FY--0.546--65.99

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-277010.770.005.02
2026Q3S2026-10-017120.770.004.99
2026Q3S2026-09-297120.770.004.99
2026Q3S2026-09-217120.770.005.00
2026Q3S2026-09-167110.770.005.02
2026Q3S2026-09-147110.780.005.03
2026Q3S2026-09-107110.780.005.03
2026Q3S2026-08-137100.770.005.00
2026Q3S2026-08-127000.750.005.04
2026Q3S2026-07-267000.750.005.02
2026Q3S2026-07-247100.750.005.02
2026Q3S2026-07-087100.740.005.00
2026Q3S2026-06-256100.030.000.20
2026Q3S2026-05-225100.040.000.20

Estimate history

EPS, annual-0.202-0.424-1.963-3.884-2.15-1.128-0.283-0.997-1.1961
Period20182019202020212022202320242025TTM
EPS, quarterly-0.186-0.232-0.309-0.27-0.343-0.275
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000026.0330.0642.95
Period20182019202020212022202320242025TTM
Sales, quarterly00.0480.01600.1692.768
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual57.50457.50457.50455.07655.04155.10355.34956.44262.974
Period20182019202020212022202320242025MRQ
Shares, quarterly55.35255.5855.78656.44262.71262.974
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2.950.0626.030.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A--0.660.721.030.630.210.110.10
Gross Profit--25.37-0.72-1.03-0.63-0.21-0.11-0.10
Selling, General and Administrative Excl. Other72.6857.4347.8368.34116.5498.6728.5716.699.95
Research and Development53.7037.8029.2653.0096.8680.3221.8715.408.96
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-70.41-58.07-22.45-69.06-117.57-99.31-28.78-16.81-10.04
Interest Expense0.000.000.000.000.020.010.420.011.50
Unusual Expense0.000.000.000.004.62104.5583.938.603.48
Net Income Before Taxes-68.80-55.28-15.41-61.99-118.07-202.37-112.89-24.40-14.19
Income Taxes0.200.200.220.120.300.260.000.000.00
Consolidated Net Income-68.99-55.48-15.63-62.11-118.37-202.63-112.89-24.40-14.19
Net Income From Continuing Operations-68.99-55.48-15.63-62.11-118.37-202.63-112.89-24.40-11.63
Net Income-68.99-55.48-15.63-62.11-118.37-202.63-112.89-24.40-11.63
EPS (Recurring)-1.10-1.00-0.28-1.13-2.09-2.48-0.94-0.32-0.16
EPS (Basic, Before Extraordinaries)-1.20-1.00-0.28-1.13-2.15-3.88-1.96-0.42-0.20
EPS (Diluted)-1.20-1.00-0.28-1.13-2.15-3.88-1.96-0.42-0.20
EBITDA-69.73-57.37-21.79-68.34-116.54-98.67-28.57-16.69-9.95
Non-Operating Income (Expense)1.622.797.057.074.141.500.231.010.83
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.222.795.054.055.088.970.800.560.09
Price To Sales Ratio50.682,452.522.93------
Gross Margin--97.46------
Operating Margin-2,384.49-90,740.63-86.24------
Net Margin-2,336.30-86,687.50-60.03------
Shares Outstanding62.9756.4455.3555.1055.0455.0857.5057.5057.50
Market Capitalization42.9642.9676.2564.9847.74296.04289.72--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue2.770.170.000.020.050.00
Cost of Goods Sold Incl. D&A-0.160.18--0.17
Gross Profit-0.01-0.18---0.17
Selling, General and Administrative Excl. Other20.2119.6115.3517.5113.3011.27
Research and Development16.2715.0311.2811.118.776.63
Other Operating Expense0.000.000.000.000.000.00
Operating Income-17.60-19.61-15.53-17.68-13.42-11.45
Interest Expense0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-17.22-19.35-15.08-17.14-12.84-10.22
Income Taxes0.060.050.030.060.060.05
Consolidated Net Income-17.28-19.40-15.11-17.20-12.90-10.27
Net Income From Continuing Operations-17.28-19.40-15.11-17.20-12.90-10.27
Net Income-17.28-19.40-15.11-17.20-12.90-10.27
EPS (Recurring)-0.27-0.34-0.27-0.31-0.23-0.19
EPS (Basic, Before Extraordinaries)-0.27-0.34-0.27-0.31-0.23-0.19
EPS (Diluted)-0.27-0.34-0.27-0.31-0.23-0.19
EBITDA-17.44-19.44-15.35-17.50-13.25-11.27
Non-Operating Income (Expense)0.380.260.440.540.581.23
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense0.950.900.690.690.710.71
Price To Sales Ratio50.68635.832,470.41---
Gross Margin-2.96----
Operating Margin-635.98-11,601.78--110,481.25-27,966.67-
Net Margin-624.42-11,478.11--107,500.00-26,872.92-
Shares Outstanding62.9762.7156.4455.7955.5855.35
Market Capitalization42.96146.47157.6584.1454.2430.39

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments44.3493.71118.30152.70267.82156.4548.7562.51
Short Term Receivables0.161.050.350.050.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets6.432.203.903.327.415.153.332.41
Total Current Assets50.9396.96122.55156.07275.23161.6052.0964.92
Net Property, Plant & Equipment4.464.244.748.4912.942.670.490.46
Total Investments and Advances0.000.000.009.460.000.000.000.00
Intangible Assets0.040.050.060.070.090.050.00-
Other Assets0.650.030.020.252.901.570.910.69
Total Assets56.08101.28127.38174.34291.16165.8953.4966.07
Short Term Debt Incl. Current Port. of LT Debt0.320.150.280.190.100.090.060.06
Accounts Payable1.960.342.2111.9612.743.773.270.50
Other Current Liabilities11.337.9722.803.515.151.950.600.36
Total Current Liabilities13.618.4625.2915.6517.995.813.930.92
Long Term Debt0.370.020.180.250.03316.8092.3883.66
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.110.630.410.000.780.000.000.00
Total Liabilities14.109.1225.8815.9018.80322.6196.3184.58
Non-Equity Reserves0.000.000.000.650.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity41.9892.17101.50157.78272.36-156.72-42.82-18.51
Total Shareholders Equity41.9892.17101.50157.78272.36-156.72-42.82-18.51
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity41.9892.17101.50157.78272.36-156.72-42.82-18.51
Total Liabilities & Stockholders Equity56.08101.28127.38174.34291.16165.8953.4966.07
Book Value Per Share0.741.671.842.874.95-2.73-0.74-0.32
Tangible Book Value Per Share0.741.661.842.874.94-2.73-0.74-0.32
Full-Time Employees64628110010862--
Price to Book Ratio1.600.690.410.221.020.90--
Return on Assets-70.51-13.76-41.17-50.86-88.67-102.92-40.82-
Return on Equity-82.72-16.18-47.91-55.04-350.47---
Return on Invested Capital-131.01-16.95-61.08-74.90-74.39-70.53-49.24-17.85
Quick Ratio3.7411.464.859.9715.3027.8113.2470.44
Current Ratio3.7411.464.859.9715.3027.8113.2470.44

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-69.99-55.48-15.63-62.11-118.07-202.37-112.89-24.40-14.19
Depreciation0.700.700.660.721.030.630.210.110.10
Other Funds (Non Cash)4.112.996.853.798.82114.0188.888.854.58
Funds from Operations-65.19-51.79-8.12-57.59-108.21-87.72-23.81-15.44-9.51
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.700.58-15.499.857.283.23-0.412.38-0.92
Cash from Operating Activities-61.49-51.21-23.61-47.74-100.93-84.49-24.22-13.06-10.43
Capital Expenditures-0.05-0.43-0.75-0.08-4.35-7.37-2.22-0.16-0.18
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.002.940.000.000.000.000.00
Purchase or Sale of Investments27.1110.25-2.7072.12-80.492.092.64-0.338.96
Purchase of Investments-4.84-30.47-15.45-31.03-115.61-17.75-15.44-23.59-16.13
Sale Or Maturity of Investments31.9540.7212.75103.1535.1219.8518.0923.2625.08
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities27.069.82-3.4574.98-84.84-5.280.42-0.488.78
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock20.051.090.230.050.13221.470.000.010.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock20.051.090.230.050.13221.470.000.010.00
Proceedsfrom Stock Options19.010.220.030.040.02221.430.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00133.350.0055.81
Change in Long Term Debt0.000.000.000.000.000.00133.350.0055.81
Issuance of Long Term Debt0.000.000.000.000.000.00133.350.0055.81
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-17.28-0.160.000.00
Other Financing Activities Uses0.000.000.000.000.00-17.28-0.160.000.00
Cash from Financing Activities20.051.090.230.05-0.09204.07133.11-0.0655.76
Exchange Rate Effect0.230.41-0.60-0.5714.11-6.26-7.740.200.40
Net Change in Cash-14.15-39.89-27.4326.72-171.76108.04101.58-13.4054.51
Free Cash Flow-61.54-51.64-24.36-47.82-105.29-91.82-26.39-13.22-10.61
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments31.4946.0344.3454.7871.7784.00
Short Term Receivables2.962.700.160.170.190.17
Inventories0.000.000.000.000.000.00
Other Current Assets4.186.296.437.645.793.58
Total Current Assets38.6255.0250.9362.6077.7687.75
Net Property, Plant & Equipment4.164.364.464.674.884.83
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.040.040.040.050.050.05
Other Assets0.650.650.650.040.040.04
Total Assets43.4760.0756.0867.3682.7292.69
Short Term Debt Incl. Current Port. of LT Debt0.390.410.320.340.350.35
Accounts Payable2.024.311.961.992.290.82
Other Current Liabilities13.8912.3311.339.108.107.40
Total Current Liabilities16.3017.0513.6111.4310.748.56
Long Term Debt0.200.290.370.450.520.59
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.110.110.110.120.120.63
Total Liabilities16.6117.4414.1011.9911.389.79
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity26.8642.6241.9855.3771.3482.90
Total Shareholders Equity26.8642.6241.9855.3771.3482.90
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity26.8642.6241.9855.3771.3482.90
Total Liabilities & Stockholders Equity43.4760.0756.0867.3682.7292.69
Book Value Per Share0.430.680.740.991.281.50
Tangible Book Value Per Share0.430.680.740.991.281.50
Full-Time Employees--64---
Price to Book Ratio1.602.642.841.180.650.33
Return on Assets-109.34-84.59----
Return on Equity-140.51-102.94----
Return on Invested Capital-63.86-45.21-35.68-30.82-17.95-12.30
Quick Ratio2.373.233.745.487.2410.25
Current Ratio2.373.233.745.487.2410.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-17.59-19.40-15.52-17.49-12.97-10.27
Depreciation0.160.160.190.180.170.17
Other Funds (Non Cash)1.281.190.880.760.670.73
Funds from Operations-16.15-18.04-14.45-16.55-12.13-9.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.042.042.85-1.15-0.53-0.59
Cash from Operating Activities-16.19-16.01-11.60-17.70-12.66-9.96
Capital Expenditures0.000.00-0.02-0.04-0.30-0.08
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-4.466.0011.1514.425.39-20.56
Purchase of Investments-4.510.00-0.15-0.18-8.00-22.56
Sale Or Maturity of Investments0.056.0011.3014.6013.392.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-4.466.0011.1314.385.08-20.64
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.4817.620.730.220.160.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.4817.620.730.220.160.00
Proceedsfrom Stock Options18.790.000.220.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.4817.620.730.220.160.00
Exchange Rate Effect0.050.070.050.060.220.07
Net Change in Cash-19.117.690.31-3.04-7.19-30.52
Free Cash Flow-16.19-16.00-11.62-17.73-12.96-10.04

Revenue breakdown

Clinical Trial Reports2024: 1.60M
Consolidation, Policy2024: 33.00K
License2024: 24.40M
Total Pharmaceutical Preparations revenue2025: 64.00K
United States2024: 26.03M 2025: 64.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3022.40%3.8M17.1M3.93M
2026-10-1522.56%3.9M17.1M3.82M
2026-09-3020.62%3.5M17.0M3.61M
2026-09-1516.35%2.8M17.0M879.44K
2026-08-3111.71%2.0M17.0M460.46K
2026-08-1410.71%1.8M17.0M414.38K
2026-07-3113.35%2.1M15.4M371.33K
2026-07-1513.37%2.1M15.4M368.63K
2026-06-308.60%1.3M15.4M328.53K
2026-06-156.87%1.1M15.5M289.28K
2026-05-297.55%1.2M15.5M269.70K
2026-05-157.41%1.2M15.6M253.86K
2026-04-308.82%1.1M12.9M247.08K
2026-04-157.73%1.0M12.9M224.17K
2026-03-314.17%0.6M14.4M152.48K
2026-03-132.66%0.4M14.3M104.77K
2026-02-272.13%0.3M14.3M110.31K
2026-02-132.10%0.3M14.3M278.82K
2026-01-302.06%0.3M13.9M281.67K
2026-01-151.96%0.3M13.9M269.22K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.001.000.440.00030.000.000.0000.0000.000
call1.000.000.050.300.00083.000.000.0000.0000.000
call1.500.001.000.004.6160.000.000.236-0.0090.000
call2.000.000.050.005.4690.000.000.212-0.0090.000
call2.500.000.050.056.08251.000.000.197-0.0100.000
call5.000.001.000.008.0870.000.000.172-0.0130.000
call7.500.001.000.039.0741.000.000.163-0.0140.000
put0.500.001.000.000.0000.000.000.0000.0000.000
put1.000.051.050.300.00010.000.00-0.701-0.0060.000
put1.500.351.350.0018.5290.000.00-0.764-0.0080.000
put2.000.851.850.0019.3980.000.00-0.788-0.0100.000
put2.501.352.350.0020.0440.000.00-0.801-0.0100.000
put5.003.804.803.7019.9741.000.00-0.828-0.0120.000
put7.506.307.300.0021.0550.000.00-0.837-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-03SCHEDULE 13G/ASEC
2026-10-06SCHEDULE 13GSEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-308-KCurrent report2026-09-30SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-01EFFECTEffectiveness filing by commission orderSEC
2026-05-28CORRESPSEC
2026-05-22UPLOADUpload SubmissionSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-238-KCurrent report2026-04-23SEC
2026-04-14SCHEDULE 13GSEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-01SCHEDULE 13D/ASEC
2026-04-014Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-308-KCurrent report2026-03-29SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05371.61K100
2026-040000
2026-034.00M100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Ikarian Capital, LLC7.21%
BML Capital Management, LLC6.14%
683 Capital Management, LLC2.04%
BOOTHBAY FUND MANAGEMENT, LLC1.55%
BlackRock, Inc.1.38%
PERCEPTIVE ADVISORS LLC1.26%
ADAR1 Capital Management, LLC1.11%
SILVERARC CAPITAL MANAGEMENT, LLC0.87%
Richmond Brothers, Inc.0.85%
Quinn Opportunity Partners LLC0.80%

Funds

Fund% owned
iShares Russell 2000 ETF0.61%
iShares Russell 2000 Growth ETF0.60%
Fidelity Small Cap Index Fund0.26%
VANGUARD RUSSELL 2000 INDEX FUND0.14%
iShares Micro-Cap ETF0.08%
Schwab Small-Cap Index Fund0.06%
Fidelity Nasdaq Composite Index Fund0.05%
Nuveen Small Cap Blend Index Fund0.03%
STATE STREET SMALL/MID CAP EQUITY INDEX PORTFOLIO0.02%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.02%

OakChart. CNTB. Cached 15 minutes.